Deep Dive: Deep Dive Into Ibrexafungerp Approval

The US Food and Drug Administration recently approved ibrexafungerp (Brexafemme; Scynexis) for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC), otherwise known as chronic yeast infections. Now, ibrexafungerp is approved for the treatment of both vulvovaginal candidiasis and the reduction in the incidence of RVVC. Marco Taglietti, MD, president and CEO of Scynexis, sits down with Contemporary OB/GYN® to discuss this recent approval and what it means for the chronic yeast infection landscape.